FDA issues blood centre/xenotransplant guidance:
This article was originally published in Clinica
The US FDA has recommended that blood centres indefinitely defer collecting blood or plasma from recipients of a xenotransplant and their intimate contacts. The February 1 guidance document also contains recommendations on how to dispose of blood products manufactured from a donor who is discovered to have received a xenotransplant after the fact or to have been an intimate contact of a recipient of a xenotransplant. This is the second draft of the guidance document, altered to incorporate revisions based on public comments to the first draft published in the Federal Register on December 30 1999.